PNPO deficiency is a rare genetic metabolic epilepsy caused by biallelic pathogenic variants in PNPO, the gene that encodes pyridox(am)ine 5′-phosphate oxidase. This enzyme is needed to convert several forms of vitamin B6 into pyridoxal 5′-phosphate (PLP), the biologically active form used by many enzymes in the brain.
The disorder matters because seizures are often severe, begin very early in life and can be resistant to ordinary antiseizure medicines — yet they may respond dramatically to the correct vitamin B6 treatment. Early recognition is important because prolonged uncontrolled seizures are associated with greater risk of neurodevelopmental impairment.
What PNPO normally does
Vitamin B6 exists in several related chemical forms, sometimes called vitamers. PLP is the active cofactor used in many biochemical reactions, including reactions involved in neurotransmitter synthesis and amino-acid metabolism.
The PNPO enzyme helps convert pyridoxine phosphate and pyridoxamine phosphate into PLP. When PNPO activity is severely reduced, the brain may not be able to maintain enough active PLP for normal neurotransmitter metabolism and neuronal function.
Why seizures occur
PLP is required by multiple enzymes involved in the production and regulation of neurotransmitters. A shortage of available PLP can disturb inhibitory and excitatory signalling across developing brain networks.
This does not create one single seizure pattern. Instead, affected newborns and infants may develop a range of seizure types that can be difficult to control with standard antiseizure medicines.
When do seizures begin?
GeneReviews describes a classic neonatal-onset form in about 90% of affected people and a later-onset form in about 10%. In the classic form, seizures often begin on the first day of life and usually before two weeks of age.
Some families report unusual rhythmic movements before birth, fetal distress or low Apgar scores, but these findings are not present in every case and are not specific to PNPO deficiency.
What seizure types can occur?
The seizure semiology is variable. Reported patterns include tonic, clonic, myoclonic and focal seizures, as well as prolonged seizures and status epilepticus.
Because neonatal seizures can be subtle, some events may be visible mainly on EEG rather than through obvious convulsive movement. Continuous or prolonged EEG monitoring can therefore be important in critically ill newborns.
Why ordinary antiseizure medicines may fail
The fundamental problem in PNPO deficiency is not simply excessive neuronal firing. It is impaired production of an essential metabolic cofactor. Antiseizure medicines may reduce seizure activity temporarily, but they do not correct the underlying PLP shortage.
This is why persistent neonatal seizures despite appropriate first-line treatment should prompt consideration of metabolic and genetic causes, including vitamin B6-dependent epilepsies.
PLP-responsive and pyridoxine-responsive disease
An important feature of PNPO deficiency is that people do not all respond to the same vitamin B6 form. GeneReviews reports that around 60% of affected individuals respond to lifelong treatment with pyridoxal 5′-phosphate, while around 40% respond to pyridoxine.
This means that the older assumption that PNPO deficiency is always “PLP-dependent” is too simple. Treatment response varies with genotype and residual enzyme activity.
What is a vitamin B6 trial?
When a severe vitamin B6-dependent epilepsy is suspected, clinicians may give pyridoxine or PLP under controlled conditions and observe clinical and EEG response.
A favourable response is an important clue, but it does not prove PNPO deficiency. ALDH7A1-related pyridoxine-dependent epilepsy, PLPBP deficiency and several other metabolic disorders can also respond to vitamin B6 treatment.
Why the first treatment must be monitored
Pharmacological vitamin B6 is not the same as an ordinary nutritional supplement. Initial treatment can cause marked sleepiness, hypotonia, respiratory depression or apnoea in some infants.
For that reason, diagnostic treatment in a critically ill newborn should be performed in a clinical setting with appropriate cardiorespiratory monitoring and respiratory support available.
How the diagnosis is confirmed
The diagnosis is usually confirmed by finding pathogenic or likely pathogenic variants affecting both copies of PNPO. Genetic testing may be performed through a neonatal epilepsy panel, developmental and epileptic encephalopathy panel, exome sequencing or genome sequencing.
Specialised enzyme studies may occasionally be used, but molecular genetic testing is now central to diagnosis.
Biochemical clues
Biochemical testing can help distinguish PNPO deficiency from other vitamin B6-dependent epilepsies. For example, elevated alpha-aminoadipic semialdehyde strongly suggests ALDH7A1 deficiency rather than PNPO deficiency.
No single routine blood test confirms PNPO deficiency, and some biochemical abnormalities can change after treatment. Results therefore need specialist interpretation.
EEG findings
There is no single diagnostic EEG pattern. EEG may show burst suppression, multifocal epileptiform discharges, abnormal background activity or other patterns seen in neonatal developmental and epileptic encephalopathies.
Improvement after treatment can take hours or days. An immediate EEG normalisation is therefore not required for a treatment response to be clinically meaningful.
MRI findings
Brain MRI can be normal or show non-specific abnormalities. PNPO deficiency is primarily a biochemical disorder rather than a condition defined by one structural lesion.
MRI remains important because neonatal seizures have many possible structural, vascular, infectious and metabolic causes that need to be considered.
Developmental outcome
Developmental outcome is highly variable. GeneReviews reports that about 60% of affected individuals have some degree of developmental impairment involving speech, cognition or behaviour. Hypotonia and dystonia can also occur.
More severe impairment is associated with delayed diagnosis and prolonged uncontrolled seizures, which is why early recognition and treatment are so important.
Long-term treatment
People with confirmed PNPO deficiency need lifelong treatment with the vitamin B6 form that controls their seizures. The lowest effective specialist-prescribed dose is generally used.
Some people may still need additional antiseizure medicines, particularly when seizure control is incomplete or when epilepsy has already become established before metabolic treatment begins.
Monitoring PLP treatment
High-dose PLP requires specialist monitoring. GeneReviews reports liver toxicity in some individuals receiving prolonged high-dose treatment, including rare severe liver injury.
Because PLP preparations can also be chemically unstable and photosensitive, formulation, storage and administration matter. Availability differs between countries, and in many regions PLP is supplied as a specialist or unlicensed medicine rather than a routine pharmacy product.
Monitoring pyridoxine treatment
Long-term excessive pyridoxine exposure can cause peripheral neuropathy. Treatment doses for vitamin B6-dependent epilepsy are pharmacological rather than nutritional, so they should be prescribed and monitored by clinicians familiar with the condition.
Inheritance
PNPO deficiency is inherited in an autosomal-recessive pattern. Typically, each parent carries one altered copy of PNPO and is not affected.
For each pregnancy between two carrier parents, the usual Mendelian risks are 25% affected, 50% carrier and 25% unaffected and not a carrier. Genetic counselling can explain these risks and discuss family testing and reproductive options.
Worldwide access
The treatment concept sounds simple — replace the missing vitamin B6 activity — but diagnosis and long-term care may be difficult in health systems without neonatal EEG, rapid genomic testing, metabolic expertise or access to pharmaceutical-grade PLP.
Some regions may have ready access to pyridoxine but not PLP, while others may lack molecular confirmation. These differences can affect which treatment is tried first and how quickly a precise diagnosis is reached.
PNPO deficiency is not ordinary vitamin B6 deficiency
This disorder is caused by a genetic failure to process vitamin B6 normally. It is not caused by eating too little vitamin B6 and cannot be managed simply by increasing dietary intake.
Standard over-the-counter supplements are not equivalent to the pharmacological treatment used for PNPO deficiency.
The central point
PNPO deficiency is a treatable metabolic epilepsy in which identifying the exact biochemical defect can transform management. But treatment response alone is not enough to identify the disorder: genomic confirmation matters because PNPO, ALDH7A1 and PLPBP disease can look similar while requiring different long-term strategies.
Related reading
Vitamin B6-Dependent Epilepsies →
Pyridoxine-Dependent Epilepsy (ALDH7A1) →
Metabolic Epilepsies →
Genetic Testing in Epilepsy →
Sources
Medical note: pyridoxine and pyridoxal 5′-phosphate at therapeutic doses are medical treatments. They should not be used as a home diagnostic test or started, stopped or switched without specialist supervision.
Evidence checked: September 2026.